Atorvastatin in open heart surgery

Not Applicable

• Conditions: Condition 1: Coronary artery bypass graft. Condition 2: Diabet melitus. Condition 3: Atrial fibrilation. Condition 4: Deliriom. Condition 5: Acute myocardial ischemia and infarction.; Mechanical complication of coronary artery bypass and valve grafts; Insulin-dependent diabetes mellitus-Non-insulin-dependent diabetes mellitus; Atrial fibrillation and flutter; Delirium, not induced by alcohol and other psychoactive substances; Acute myocardial infarction; E10-11

• Registration Number: IRCT2012072310311N2
• Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

patients admitted in Nemazee hospital who underwent CABG on CPB; after learning of the investigation and completed an informed consent, were randomized to receive atorvastatin are divided into two groups. Exclusion criteria: unstable angina; myocardial infarction; evidence of recent MI (within 6 months); history of previous cardiac surgery; emergency surgery; congenital heart disease; a history of cardiac arrhythmias (Atrial Fibrilation) preoperatively received antiarrhythmic drugs (except Beta blocker); having Pacemaker; Left Ventricle Edjection Fraction less than 30%; uncontrolled hypertension; persistant atrial or ventricular arrhythmia; pregnant women; a history of diabet under treatment; elevated liver enzymes; renal failure with creatinine greater than 2mg/dl; inflammation or immune activation; muscle disease and alergy to statins.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
CK-MB. Timepoint: Befor induction, 24 and 48 h after surgery. Method of measurement: Labratory kit.;CRP. Timepoint: Befor induction, 24 and 48 h after surgery. Method of measurement: Laberatory kit.;Blood suger. Timepoint: Before induction, in pump, after off pump, every 6h upto48 h, then daily. Method of measurement: Glucometr.;Atrial fibrilation. Timepoint: During operation, in course of ICU admission. Method of measurement: Continioues ECG monitoring.;MACE(magor adverse cardiac events). Timepoint: In ICU and up to 1 month after surgery. Method of measurement: Echocardiography.

Secondary Outcome Measures

Name	Time	Method
Ceratinin. Timepoint: Before surgery, daily up to 3 days. Method of measurement: Laberatory kit.;Hematocrit. Timepoint: Before surgery,in pump,off-pump,days of 1&2&3. Method of measurement: Laberatoty kit.;Liver function tests. Timepoint: Befor surgery,second day after operation. Method of measurement: Lab kit.;Delirium. Timepoint: In course of ICU admission. Method of measurement: Richmond scale daily.